# EVERST- Everolimus After Alpelisib in Women With Hormone Receptor-positive (HR+) Metastatic Breast Cancer (MBC)

> **NCT07646171** · — · RECRUITING · sponsor: **Tel-Aviv Sourasky Medical Center** · enrollment: 19 (estimated)

## Conditions studied

- Hormone Receptor Positive Breast Cancer

## Interventions

- **DRUG:** Everolimus (Afinitor) tablets with endocrine therapy
- **PROCEDURE:** Blood draw for biomarker and genetic analysis

## Key facts

- **NCT ID:** NCT07646171
- **Lead sponsor:** Tel-Aviv Sourasky Medical Center
- **Sponsor class:** OTHER_GOV
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** RECRUITING
- **Start date:** 2022-09-01
- **Primary completion:** 2026-12-31
- **Final completion:** 2027-12-31
- **Target enrollment:** 19 (ESTIMATED)
- **Last updated:** 2026-06-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07646171

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07646171, "EVERST- Everolimus After Alpelisib in Women With Hormone Receptor-positive (HR+) Metastatic Breast Cancer (MBC)". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07646171. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*